Insider · CIK 0001827326

Eisele Jeffrey

Reports to the SEC for 1 company · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001827326

Forms 4 and 5

Insider transactions

35 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-01-29	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−278 sh	$29.52	−$8,207.561	55,312
2025-01-22	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−1,291 sh	$30.43	−$39.3K	55,590
2025-01-13	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−264 sh	$28.70	−$7,577.354	56,881
2024-12-23	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−63 sh	$33.09	−$2,084.67	57,145
2024-01-30	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−971 sh	$65.53	−$63.6K	57,208
2024-01-29	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−279 sh	$64.14	−$17.9K	58,179
2024-01-23	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−7,378 sh	$63.69	−$470K	58,458
2024-01-22	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−1,607 sh	$65.00	−$104K	65,836
2024-01-17	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−5,207 sh	$65.58	−$341K	67,443
2024-01-16	APLSApellis Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+19.5K sh	—	—	73,088
2024-01-16	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−438 sh	$66.81	−$29.3K	72,650
2024-01-16	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+28.4K sh	$66.30	+$1.88M	28,367
2023-12-27	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−235 sh	$60.23	−$14.2K	53,580
2023-12-26	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−68 sh	$57.86	−$3,934.541	53,815
2023-02-23	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−1,646 sh	$68.76	−$113K	53,883
2023-02-21	APLSApellis Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+9,886 sh	—	—	56,354
2023-02-21	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−825 sh	$58.50	−$48.3K	55,529
2023-02-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+14K sh	—	—	14,023
2023-01-30	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−883 sh	$52.76	−$46.6K	46,468
2023-01-27	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−367 sh	$52.77	−$19.4K	47,351
2023-01-23	APLSApellis Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−4,479 sh	$51.58	−$231K	47,718
2023-01-20	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−2,033 sh	$52.05	−$106K	52,197
2023-01-12	APLSApellis Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+22.6K sh	—	—	54,230
2023-01-12	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+35.5K sh	$52.66	+$1.87M	35,472
2022-12-22	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−89 sh	$51.68	−$4,599.52	31,650
2022-04-25	APLSApellis Pharmaceuticals, Inc.J Other	Chief Development Officer	JOther	−1,250 sh	—	—	31,739
2022-01-28	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−434 sh	$38.59	−$16.7K	32,989
2022-01-21	APLSApellis Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+26.1K sh	—	—	33,423
2022-01-21	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+37K sh	—	—	36,951
2021-12-22	APLSApellis Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−89 sh	$47.82	−$4,255.98	7,372
2021-03-01	APLSApellis Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+1,250 sh	—	—	7,461
2021-03-01	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+7,500 sh	—	—	7,500
2021-01-28	APLSApellis Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+5,000 sh	—	—	6,211
2021-01-28	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+30K sh	—	—	30,000
2020-12-23	APLSApellis Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+1,211 sh	—	—	1,211

Recent filings

Accepted (ET)
Jan 304
Eisele Jeffrey0001127602-25-002379
SEC(opens sec.gov)
Jan 234
Eisele Jeffrey0001127602-25-001835
SEC(opens sec.gov)
Jan 144
Eisele Jeffrey0001127602-25-001193
SEC(opens sec.gov)
Dec 274
Eisele Jeffrey0001127602-24-030106
SEC(opens sec.gov)
Jan 314
Eisele Jeffrey0001127602-24-002738
SEC(opens sec.gov)
Jan 244
Eisele Jeffrey0001127602-24-002012
SEC(opens sec.gov)
Jan 234
Eisele Jeffrey0001127602-24-001943
SEC(opens sec.gov)
Jan 184
Eisele Jeffrey0001127602-24-001603
SEC(opens sec.gov)
Jan 174
Eisele Jeffrey0001127602-24-001380
SEC(opens sec.gov)
Dec 284
Eisele Jeffrey0001127602-23-030552
SEC(opens sec.gov)
Feb 274
Eisele Jeffrey0001127602-23-007327
SEC(opens sec.gov)
Feb 224
Eisele Jeffrey0000899243-23-005787
SEC(opens sec.gov)
Jan 314
Eisele Jeffrey0001127602-23-002753
SEC(opens sec.gov)
Jan 304
Eisele Jeffrey0001127602-23-002682
SEC(opens sec.gov)

Companies

Apellis Pharmaceuticals, Inc.Chief Development OfficerAPLS

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451